Information

  • Dec 13, 2024

Here's What the Latest Bitcoin Rally Can Tell Us About the State of Crypto in 2025

The recent Bitcoin (CRYPTO: BTC) post-election rally has crypto investors looking ahead with anticipation to 2025. Bitcoin is up 125% for the year as of Dec. 10 and has finally broken through the psychologically important $100,000 price level to set a new all-time high. Will Bitcoin turn in an encore performance and once again deliver triple-digit returns?

  • Dec 13, 2024

Americans are sour on tariffs if they spark inflation, Reuters/Ipsos poll finds

Americans don't think import tariffs are a good idea if they lead to higher prices and are skeptical they would help U.S. workers, a Reuters/Ipsos poll found, underscoring the political risks to President-elect Donald Trump's plan to impose heavy fees on goods from China, Mexico and other nations. Only 29% of respondents in the six-day poll, which closed on Tuesday, agreed with a statement that "it’s a good idea for the U.S. to charge higher tariffs on imported goods even if prices increase," while 42% disagreed. Just 17% of respondents agreed with a statement that "when the U.S. charges tariffs on imported goods, it is good for me personally."

  • Dec 13, 2024

Fee War Kicks Off for One of Wall Street’s Hottest ETF Trades

(Bloomberg) -- Single-stock ETFs have been one of Wall Street’s hottest trades this year thanks to eye-popping returns and billions of dollars in inflows. Now, one issuer is kicking off a fee war in a bid to stand out and attract new cash. Most Read from BloombergHong Kong's Expat Party Hub Reshaped by Chinese InfluxHow California Sees the World, and ItselfBrace for a Nationwide Shuffle of Corporate HeadquartersCity Hall Is HiringAmerican Institute of Architects CEO ResignsLeverage Shares, which

  • Dec 13, 2024

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Morgan Stanley downgraded Amicus Therapeutics Inc (NASDAQ:FOLD). Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd. The analyst notes that Amicus is well-positioned, but expectations have increased with the company’s progress, which are now largely priced into shares. The analyst downgraded the stock to Equal-weight from Overweigh

  • Dec 13, 2024

US data has Fed striding toward rate cut next week, and tip-toeing into 2025

Investors view it as a near given that the U.S. Federal Reserve will cut interest rates by a quarter of a percentage point at its Dec. 17-18 meeting, with more attention focused on policymakers' new economic projections released alongside the decision. Those projections will include an updated look at how much further Fed officials think they will reduce rates in 2025 and perhaps into 2026, an exercise that will have to account for data in the meantime showing stickier-than-expected inflation, a healthy labor market, a U.S. election result that could shift the global trade and immigration landscape, and ongoing geopolitical risks. With so much to assess, a multitude of new risks, and a lot of uncertainty, many analysts expect the collective messaging from the central bank's policy statement on Wednesday, Fed Chair Jerome Powell's post-meeting press conference and the updated projections to be somewhat hawkish - with the Fed perhaps closer to a rate-cut stopping point, or at least very reluctant to commit to many more reductions in borrowing costs, than it was just a few months ago.

  • Dec 13, 2024

US data has Fed striding toward rate cut next week, and tip-toeing into 2025

Investors view it as a near given that the U.S. Federal Reserve will cut interest rates by a quarter of a percentage point at its Dec. 17-18 meeting, with more attention focused on policymakers' new economic projections released alongside the decision. Those projections will include an updated look at how much further Fed officials think they will reduce rates in 2025 and perhaps into 2026, an exercise that will have to account for data in the meantime showing stickier-than-expected inflation, a healthy labor market, a U.S. election result that could shift the global trade and immigration landscape, and ongoing geopolitical risks. With so much to assess, a multitude of new risks, and a lot of uncertainty, many analysts expect the collective messaging from the central bank's policy statement on Wednesday, Fed Chair Jerome Powell's post-meeting press conference and the updated projections to be somewhat hawkish - with the Fed perhaps closer to a rate-cut stopping point, or at least very reluctant to commit to many more reductions in borrowing costs, than it was just a few months ago.

  • Dec 13, 2024

Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst

BofA Securities reports that the Life Sciences Tools sector struggled in fiscal year 2024. Spending by pharmaceutical and biotech companies dropped after pandemic-related overspending, and demand in China stayed weak. This led some Life Sciences companies to lower their already-conservative fiscal year revenue forecasts as the year progressed. For most of fiscal year 2024, Life Sciences company valuations remained higher than pre-COVID levels but declined after the U.S. elections. Looking ahead

Popular Post